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Background: Campylobacter jejuni is an important food-borne and zoonotic pathogen with a worldwide distribu-
tion. Humans and chickens are hosts of this pathogen. At present, there is no ideal vaccine for controlling
human campylobacteriosis or the carriage of C. jejuni by chickens. Bacterial in vivo-induced antigens are useful
as potential vaccine candidates and biomarkers of virulence.
Methods: In this study, we developed a novel systematic immunoproteomics approach to identify in vivo-induced
antigens among the total cell proteins of C. jejuni using pre-adsorbed sera from patients infected with C. jejuni.
Results: Overall, 14 immunoreactive spots were probed on a PVDF membrane using pre-adsorbed human sera
against C. jejuni. Then, we excised these protein spots from a duplicate gel and identiﬁed using MALDI–TOF MS.
In total, 14 in vivo-induced antigens were identiﬁed using PMF and BLAST analysis. The identiﬁed proteins include
CadF (CadF-1 and CadF-2), CheW, TufB, DnaK, MetK, LpxB, HslU, DmsA, PorA, ProS, CJBH_0976, CSU_0396 and
hypothetical protein cje135_05017. Real-time RT-PCR was performed on 9 genes to compare their expression
levels in vivo and in vitro. The data showed that 8 of the 9 analyzed genes were signiﬁcantly upregulated in
vivo relative to in vitro.
Conclusion: We successfully developed a novel immunoproteomics method for identifying in vivo-induced
Campylobacter jejuni antigens by using pre-adsorbed sera from infected patients.
General signiﬁcance: This new analysis method may prove to be useful for identifying in vivo-induced antigens
within any host infected by bacteria and will contribute to the development of new subunit vaccines.
© 2013 The Authors. Published by Elsevier B.V.Open access under CC BY license.1. Introduction
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.V. Open access under CC BY license.human bacterial food-borne diarrheal disease worldwide, especially in
many industrialized countries [2]. Children are especially susceptible
to C. jejuni in both developed and developing countries [3,4]. C. jejuni
can colonize the lower intestines of many hosts, including humans,
chickens, cattle, sheep [5], dogs, and wild birds [6]. In humans, C. jejuni
infection can induce self-limiting diarrhea [3]. Guillain–Barré syndrome
(GBS) is an acute polyneuropathy [1,7] with a global incidence of 0.6–4
cases per 100,000 people. This disease generally occurs after infection
by C. jejuni from contaminated food or water [3,8–10]. Evidence sug-
gests that GBS results frommolecular mimicry due to the similarity be-
tween GM1 and GD1a gangliosides and the lipooligosaccharides (LOS)
of C. jejuni [2,11]. There are a number of Campylobacter antigens during
infection, including in vivo or in vitro expressed virulence-associated
factors. However, the antibodies response to diarrhea is different to
GBS infected by C. jejuni [12,13]. Unlike other diarrhea-causing bacteria,
C. jejuni does not express many classical virulence factors, such as pilus
structures [1,4]. However, C. jejuni contains O- and N-linked glycosyla-
tion systems. Due to the limited information on the pathogenicity of C.
jejuni within its hosts, an effective vaccine for C. jejuni, which may
help to control infections, is lacking [14].
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goal for many years, and most vaccine studies have concentrated on
whole-cell and subunit vaccines [14]. The Naval Medical Research
Center (NMRC) used killed C. jejuni cells as vaccine to immunize
mouse andmonkeymodels, and their results showed its signiﬁcant pro-
tective effect. Unfortunately, this vaccine is not used in clinical settings
even though a Phase II clinical trial was conducted and showed efﬁcacy
[14,15]. Subunit vaccines are the safest vaccines, but their efﬁcacy is
lower than whole-cell vaccines. The maltose-binding protein (MBP)-
FlaA protein vaccine was proven to protect mice from colonization,
but its application in immunoprophylaxis was problematic [16]. Anti-
gens that are induced in vivo when pathogens infect their hosts may
be crucial factors, and some may elicit a protective effect [14].
In vivo-induced antigens are important virulence-associated factors,
and these proteins are considered major pathogenicity-related mole-
cules involved in the interactions between hosts and microorganisms.
Due to the lack of an ideal animal model to study the pathogenicity of
C. jejuni in humans, the identiﬁcation of in vivo-induced antigens was
hampered for a long time. In 2008, Malik-Kale [17] demonstrated that
culturing C. jejuniwith sodiumdeoxycholate (DOC) induces the expres-
sion of virulence genes, and these culture conditions mimic the in vivo
environment, obviating the need for animal models.
Immunoproteomics has been used to identify immunoreactive pro-
teins frommanymicroorganisms, such as Streptococcus suis [18,19] and
Helicobacter pylori [20]. However, there is no report of the analysis of
C. jejuni using immunoproteomics. In this study, to remove the antibod-
ies induced by in vitro antigens, patient sera were pre-adsorbed 6 times
with C. jejuni whole cells, cell lysates and secreted protein. We used
these pre-adsorbed sera to probe two-dimensional electrophoresis
(2-DE) gels of C. jejuni whole-cell proteins from C. jejuni cultured in
the presence of DOC tomimic the in vivo environment. These identiﬁed
proteins were assumed to be in vivo-induced antigens and identiﬁed
using matrix-assisted laser desorption ionization–time of ﬂight mass
spectrometry (MALDI–TOF MS). A schematic diagram of the detection
method for the in vivo-induced antigens is shown in Fig. 1. The identi-
ﬁed in vivo-induced factors may be candidate antigens for preventing
disease caused by C. jejuni or diagnostic markers. The novel method
was embodied in 3 ﬁelds of improvement. Firstly, it does not depend
on Escherichia coli expression of proteins in vitro away, avoiding the
irregular protein expression. Secondly, DOC culture conditions mimic
the in vivo environment, obviating the need for animal models. Thirdly,
the method is a systematic immunoproteomics approach to identify in
vivo-induced antigens among the total cell proteins with C. jejuni.Pooled sera Infected by C. jejuni
C. jejuni on CCDA C. jejuni o
Antibodies
vivo-induce
Removed antibodies 
Fig. 1. Schematic diagram of the immunoproteomics assay to identify in vivo-induced antige
antibodies that recognize in vivo-induced antigens produced by C. jejuni grown on DOC plate
gels of whole proteins from C. jejuni cultured under DOC culture conditions. Spots that appea
after C. jejuni infects humans. DOC plates were prepared using CCDA medium plus 0.1% sod2. Materials and methods
2.1. Bacteria and culture conditions
C. jejuni strain NCTC 11168, which was kindly provided by
Dr. Wanbang Sun from Zunyi Medical College in China, was cultured
on Campy blood-free selectivemedium (CCDA) (Oxoid Ltd., Basingtoke,
Hampshire, England) plates at 42 °C under microaerobic conditions.
To induce the expression of in vivo-induced antigens, C. jejuni strain
NCTC 11168 was cultured on CCDA medium containing 0.1% sodium
deoxycholate (DOC, Sigma, USA) [17] (referred to as DOC plates) for
15 h under microaerobic conditions.
2.2. Preparation of pre-adsorbed anti-sera
In this study, human sera were obtained from 7 clinical volunteers
(Subei Hospital of Yangzhou, China) who had previously suffered from
repeated diarrhea due to C. jejuni infection. These patients were more
than 50 years old, and although they reported suffering from repeated
episodes of diarrhea during the interview, they never sought medical
advice until general health survey. Human sera experiments were
conducted in accordance with national guidelines and were approved
by Subei Hospital of Yangzhou and each patient. The antibody levels
of these sera were determined using an indirect ELISA kit (SERION
ELISA classic CAMPYLOBACTER JEJUNI IgG, Virion\Serion, Wurzburg,
Germany). Sera that were pooled in equal portions were sequentially
adsorbed using C. jejuni whole NCTC 11168 cells, ultrasonic lysates,
inactivated lysates and secreted proteins. Firstly, whole cells mixing
with sera was performed on a rocking platform (Incubator Shaker,
Crystal, China) at 4 °C for 1 h and repeated 6 times. The subsequent
adsorption steps were performed 6 times using PVDF membranes
coated with the in vitro antigens. Each adsorption step was performed
at 4 °C on a rocking platform for 1 h. Aliquots of the ﬁnal adsorbed
sera were stored at −80 °C for 2-D blotting. Indirect ELISAs were
performed to evaluate the adsorption of the anti-in vitro antigen anti-
bodies in the sera by coating the plates with C. jejuni NCTC 11168
whole cells, lysates, CjaA, recombinant FlaA370 protein (prepared
previously in our laboratory) and total ﬂagellum protein [21].
2.3. Protein sample extraction
Whole-cell proteins from C. jejuni were extracted according to the
protocol of Zhang [22], with minor modiﬁcations. Brieﬂy, C. jejuni cellsMALDI-TOF MS
n DOC Proteins of whole cell 
against in
d antigens
Duplicate gels
2-D Western blotting 
ns. Sera from 7 patients infected with C. jejuniwere pooled and pre-adsorbed to enrich
s, which mimic in vivo conditions. Then, the pre-adsorbed sera were used to probe 2-DE
red in the 2-DWestern blotting were assumed to be in vivo-induced antigens expressed
ium deoxycholate.
Table 1
Primers used for real-time RT-PCR analysis.
Genes Primer Sequence (5′–3′)
dnaK dnaK-F TCAATGAGCCTACTTCAGCA
dnaK-R TTCAAGCGTTGCAAAGCCAT
tufB tufB-F TGACTTACTCCACACACTGACTTCG
tufB-R CATACCTTTTCACCTGGCATAACC
metK metK-F CAATCAAGAAGATGGCGAAACAG
metK-R CATACTTTCAACACAAGGTGCAGA
cadF cadF-F CGGTGGATTTGGACATTATGGC
cadF-R GAGGACATTTTGCTTGTGGAGTT
hslU hslU-F GAAGTAGGTTTTGTAGGTCGTGATG
hslU-R GCAGGAGGTAGGTTGGGATT
proS proS-F CACAAGATCACAAGCTATAAACAAC
proS-R TTCCTTAGAGCCACTTCCACCA
porA porA-F GCGGACAATTCAACCCACA
porA-R CGAAGGCTAGCATCCCAACC
cheW cheW-F TATGCGTGGTAATGTTATGCCG
cheW-R ACTAAAGTTTCAGGTGGTGGATCG
CSU-0396 CSU-0396-F AAGGACTATGTTCAATTTTGGGAA
CSU-0396-R CGCTTATGAGGCGAAGTTTTT
glyA Cj0402-F CGATGGAACGGATAATCACC
Cj0402-R AATACCTGCATTTCCAAGAGC
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Fig. 2. The results of the indirect ELISA analysis of human sera using 5 antigens after
each adsorption step. The whole cells of C. jejuni NCTC 11168, lysates from C. jejuni,
recombinant CjaA, FlaA370 protein and ﬂagellum protein were used as coating antigens
to analyze the pre-adsorbed sera. Sample S0 was the pooled sera from 7 patients before
adsorption. Samples S1 to S4 were the sera recovered after successive adsorption with
C. jejuni NCTC 11168 whole cells, ultrasonic lysates, inactivated lysates and secreted
proteins.
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washed 3 times in saline by centrifugation at 6,000 rpm at 4 °C for
10 min. The C. jejuni pellet was resuspended in lysis buffer (6 M urea,
2 M thiourea, 4.0% [w/v] CHAPS, 40 mM DTT and 0.5% [v/v] IPG
pH 3–10 buffer) and sonicated in an ice bath several times for 20 s at
20 s intervals until the suspension became clear. The bacterial debris
was removed by centrifugation at 12,000 rpm at 4 °C for 15 min. The su-
pernatant was further processed using the 2D-clean up kit (Bio-Rad Lab-
oratories, Inc., Hercules, CA, USA) and quantiﬁed using the 2D-Protein
Assay Kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA) according to
the manufacturer's instructions. The supernatant was then subjected to
2-DE.
2.4. IEF of whole-cell proteins
Isoelectric focusing (IEF) was performed using a Bio-Rad Protean
IEF system (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and 17 cm
(pH 4–7) gel strips (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Each strip was loaded with 300 μg of protein, and IEF was carried out
at 17 °C for 12.5 h (maximum voltage of 10,000 V and maximum
current of 50 μA per IPG strip).
2.5. 2-D SDS-PAGE and Western blotting
Duplicate gels were prepared for each 2-D SDS-PAGE run. Each
IPG strip was washed with equilibration buffer 1 (375 mM Tris–
HCl [pH 8.8], 6 M urea, 2% SDS, 2% DTT) for 15 min and with equil-
ibration buffer 2 (375 mM Tris–HCl [pH 8.8], 6 M urea, 2% SDS,
2.5% iodoacetamide) for 15 min. Each IPG strip was loaded into a
homogeneous 12% polyacrylamide gel and sealedwith 1% agarose. Elec-
trophoresis was performed at 15 °C and 100 V for 30 min followed by
300 V until the tracking dye reached the bottom of the gel. One gel
was stained with colloidal Coomassie brilliant blue G-250 according
to the manufacturer's instructions, and another gel was used for 2-D
Western blotting.
The proteins within the SDS-PAGE gels were electrophoretically
transferred onto PVDF membranes (Amersham Biosciences, Piscataway,
NJ, USA) using a semidry blotting apparatus (Amersham Biosciences,
Piscataway, NJ, USA). The electrotransfer time was 120 min, with a
current/area of 0.8 mA/cm2. After being blocked with 1% w/v BSA in
PBS (pH 7.4) for 2 h at room temperature, the membranes were incu-
bated with pre-adsorbed sera (1:1000 dilution) for 120 min at room
temperature and subsequently washed three times with 0.05% w/v
Tween-20 in PBS for 10 min. Immunodetection was performed with
goat anti-human horseradish peroxidase (HRP) secondary antibodies,
and the reactive spots were visualized using a chemiluminescent ECL
substrate (Thermo, USA) at room temperature. The membranes were
washed three times with 0.05% w/v Tween-20 in PBS for 10 min before
and after the addition of the secondary antibody.
2.6. MALDI–TOF MS and database searching
Proteins identiﬁed by the 2-D blotting as potential in vivo-induced
antigens were excised from the duplicate gel and analyzed with
MALDI–TOF MS (TOF Ultraﬂex II mass spectrometer, Bruker Daltonics).
The peptide mass ﬁngerprinting (PMF) data were analyzed using the
MASCOT server (http://www.matrixscience.com). MASCOT searches
were performed to identify peptides that were considered signiﬁcant
and used to determine the combined peptide scores. The extent of
sequence coverage, the number of matched peptides, and the probabil-
ity score obtained from the PMF data were all used to validate the pro-
tein identiﬁcations. Low-scoring proteins were either veriﬁedmanually
or rejected. Signal peptides in the proteins were analyzed using the
SignalP 4.0 server (http://www.cbs.dtu.dk/services/SignalP/). The se-
quences of the identiﬁed proteins were searched using the BLASTXserver (http://www.ncbi.nlm.nih.gov/BLASTX/) to ﬁnd homologous
sequences.
2.7. Real-time PCR analysis
The in vivo expression of proteins was conﬁrmed by comparing
the RNA transcript levels between the cultures grown on CCDA plates
and those grown on DOC plates [17]. After strain NCTC 11168 was
cultured for 15 h on CCDA or DOC plates, the total RNA was extracted
using TRIzol (TaKaRa, Dalian, China). Then, cDNA was synthesized
using an RT-PCR kit (TaKaRa, Dalian, China) and 500 ng of RNA
according to the manufacturer's instructions. Real-time RT-PCR
ampliﬁcation was performed in a ﬁnal volume of 20 μl containing
2.0 μl of cDNA, 16.4 μl of SYBR Premix Ex Taq II (TaKaRa, Dalian,
China), 10 μM forward primer, 10 μM reverse primer, and diethyl
pyrocarbonate-treated water. Real-time RT-PCR analysis was performed
using a Gene Amp 7500 thermocycler (Applied Biosystems, Carlsbad,
California, USA) with the following protocol: 2 min at 50 °C followed
by 40 cycles of denaturation at 95 °C for 30 s and annealing at 60 °C
for 34 s. In this study, 9 genes were selected for real-time PCR analysis.
pH4 pH7 pH4 pH7
B
P1
P2 P3 P4P8
P5
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P11
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Fig. 3. 2-DE gel and Western blotting analyses of C. jejuni NCTC 11168. (A) C. jejuni NCTC 11168 total cell proteins (pH 4–7, 17 cm) stained with colloidal Coomassie brilliant blue
G-250. (B) 2-DE blotting of C. jejuni probed with the pre-adsorbed sera.
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used to detect these 9 genes were listed in Table 1. Duplicate reactions
were analyzed, and three biological replicateswere used for each sample.
Threshold cycle values were determined using 7500 software version
2.0.1 (Applied Biosystems, Carlsbad, California, USA).
2.8. Prediction of antigenicity
To determine the antigenicity of the 14 probed antigens, the com-
plete amino acid sequences of the proteins were predicted using the
Protean program in DNAstar, and this analysis was performed based
on the Jameson–Wolf mathematical model [23].
3. Results
3.1. Pre-adsorption of patient sera
Seven positive sera from volunteers were pooled and analyzed
using a SERION ELISA IgG kit (data not shown). The adsorption of
pooled human sera was evaluated using an indirect ELISA, and the
results showed that the immunoreactivity of the pooled sera to in
vitro cultured C. jejuni antigens gradually decreased after the different
steps of the adsorption protocol (Fig. 2). Therefore, the antibodies
that developed in response to in vivo antigens when humans were
infected by C. jejuni were retained after removing most of the anti-
bodies to in vitro antigens.Table 2
Protein spots identiﬁed by MALDI–TOF-MS.
Spot No. Protein identiﬁed Gene/protein BLAST similarity matched protein
P1 gi|315930436 Cj0759/DnaK Chaperone, the heat shock protein
P2 gi|283954239 Cj0470/TufB Elongation factor TU
P3 gi|201067889 CJBH_0976 Conserved hypothetical protein
P4 gi|167005690 Cj1096c/MetK S-adenosylmethionine synthetase
P5 gi|380628970 Cj0288c/LpxB 50 kDa outer membrane protein
P6 gi|380623710 Unknown Hypothetical protein cje135_0501
P7 gi|121612147 Cj1478c/CadF-1 Fibronectin-binding protein
P8 gi|57236972 Cj0662c/HslU Chaperone, ATP-dependent prote
P9 gi|66735108 CJM1_1521/DmsA Anaerobic dimethyl sulfoxide redu
P10 gi|218562871 Cj1259/PorA Major outer membrane protein
P11 gi|315932248 CSU_0396 Sensory box protein
P12 gi|57237338 CJE0331/CheW Purine-binding chemotaxis protei
P13 gi|218562195 Cj0543/ProS Prolyl-tRNA synthetase
P14 gi|4704601 Cj1478c/CadF-2 Fibronectin binding protein3.2. 2-DE and 2-D Western blotting
Whole-cell proteins of C. jejuni cultured onDOCplateswere separated
on duplicate 2-DE gels covering a pH range of 4–7 (Fig. 3A). One gel was
stained with colloidal Coomassie brilliant blue G-250, and another gel
was used for 2-D Western blotting with the pre-adsorbed human sera.
The images of the Western blotting and duplicate gel were compared. A
total of 14 positive spots were excised from the duplicate SDS-PAGE gel
and analyzed by MALDI–TOF MS. Fourteen immunoreactive proteins
were identiﬁed using this immunoproteomics method (Fig. 3B). The
PMF results are summarized in Table 2.
3.3. Identiﬁcation of immunoreactive proteins by bioinformatic analyses
Fourteen immunoreactive protein spots were excised from the
preparative duplicate 2-DE gel and analyzed by MALDI–TOF MS. The
top-ranking protein identiﬁed in each spot and the predicted signal
peptides in these proteins are listed in Table 2. These following
in vivo-induced antigens were identiﬁed through PMF and BLAST
searches: CadF (CadF-1 and CadF-2), CheW, TufB, DnaK, MetK, LpxB,
HslU, DmsA, PorA, ProS, CJBH_0976, CSU_0396 and hypothetical pro-
tein cje135_05017. Of these proteins, LpxB, CadF and PorA have signal
peptides, indicating that these 3 proteins may be major antigens
located in the outer membrane of C. jejuni. PorA and CadF mediate
adhesion to intestinal cells. TufB, MetK, LpxB, and ProS play important
roles in molecular biosynthesis. DnaK and HslU are classiﬁed as heat
shock protein family members. CheW and CSU_0396 have functionsSignal
peptide
Theoretical
Mr/Pi
Mascot
score
No. of peptides
matched
Coverage
(%)
70 family 0.131/NO 65022/5.08 183 20 43
0.165/NO 43637/5.12 134 20 59
0.101/NO 55623/5.35 139 17 37
0.102/NO 43627/5.35 124 12 29
precursor 0.830/YES 53743/5.96 95 13 28
7 0.102/NO 34665/4.96 236 20 64
0.592/YES 36138/5.89 168 17 57
ase 0.109/NO 49747/6.00 128 15 41
ctase chain A 0.125/NO 75167/6.15 256 24 33
0.837/YES 45660/4.71 257 14 43
0.095/NO 38330/5.27 275 18 52
n CheW 0.097/NO 19504/5.48 311 9 57
0.146/NO 64564/5.96 227 30 50
0.133/NO 32338/5.60 276 12 45
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Fig. 4. The in vivo-induced gene expression level relative to the in vitro expression
level determined using real-time PCR. Nine in vivo-induced antigens were analyzed
by determining their mRNA transcription levels. C. jejuni NCTC 11168 was cultured
on CCDA plates (control, in vitro conditions) and DOC plates (in vivo-like conditions)
for 15 h, and the mRNA levels were determined by real-time PCR. Levels of transcription
greater than 1-fold were considered indicative of upregulation relative to the in vitro
control.
5233Y. Hu et al. / Biochimica et Biophysica Acta 1830 (2013) 5229–5235in chemotaxis. The functions of cje135_05017 and CJBH_0976 are
unknown. DmsA is hypothesized to be an oxidoreductase and may
be important for respiration under oxygen-restricted conditions.
3.4. Expression proﬁles of the in vivo-induced antigens
To evaluate the in vivo expression of the C. jejuni genes identiﬁed
using the immunoproteomics method, 9 of the 14 immunoreactive
proteins were selected, and their expression levels in vivo and in
vitro were compared by real-time RT-PCR. The culture methodDnaK
CJBH_0976
LpxB
CadF-1
DmsA
CSU_0396
ProS
Fig. 5. Antigenic properties of the in vivo-induced antigens predicted using a bioinformatics
program in DNAstar, and this method was performed based on the Jameson–Wolf mathe
indicating that these proteins are highly antigenic.using DOC plates, which can mimic in vivo induction conditions,
was used when analyzing RNA transcription. The real-time PCR re-
sults showed that 8 genes (dnaK, tufB, metK, cadF, proS, porA, cheW,
and csu_0396) were upregulated under in vivo-like conditions
(N1-fold); hslU was not upregulated (Fig. 4). These results indicate
that these 8 genes may be induced in vivo when humans are infected.
3.5. Antigenicity of the in vivo-induced antigens
All in vivo-induced antigens identiﬁed in this study were highly
antigenic, and the results of the prediction are shown in Fig. 5. The
antigenic indexes of these proteins were more than 1.0, indicating
that these in vivo-induced antigens are likely antigenic.
4. Discussion
C. jejuni is not environmental organism but strictly need host gut for
colonization. This pathogen is an organismubiquitously found in several
host species, including livestock andwild animals, and opportunistically
contaminated soil andwater [24,25]. Humans can be infected for exam-
ple through the consumption of chicken products contaminated with
C. jejuni. To control and decrease campylobacteriosis, we must under-
stand the pathogenesis or virulence mechanisms involved in human
infections with C. jejuni [2]. Without suitable animal model, we cannot
investigate the virulence-associated factors that are expressed in
human infections using several techniques, including in vivo expression
technology (IVET) [26], signature-tagged mutagenesis (STM) [27],
differential ﬂuorescence induction (DFI) [28], and transcriptional and
proteomic proﬁling [29]. In vivo-induced antigen technology (IVIAT) is
a method of identifying proteins that are expressed in infected hosts
[30,31]. Based on IVIAT and the superiority of avoiding the use of animal
models, we developed a novel immunoproteomicsmethod for identify-
ing in vivo-induced antigens. These antigens were identiﬁed using
pre-adsorbed sera from patients who had been infected with C. jejuni.
However, there are some drawbacks for this method used to adsorb
antibodies in vitro. Firstly, it is not expected to identify every virulenceTufB
MetK 
cje135_05017 
HslU
PorA
CheW 
CadF-2
approach. The antigenicity of the 14 identiﬁed antigens was predicted using the Protean
matical model. The antigenic propensities of the 14 antigens were greater than 1.0,
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expressed gene will not be immunogenic. Secondly, false positives can
arise because of immunological cross-reactivity. Also, this technology
purposely ignores those genes that are expressed both in vitro and in
vivo [32]. Whole-cell proteins were prepared from C. jejuni cultured
on DOC plates, which mimic the in vivo infection conditions, and the
majority of extractions contained in vivo-induced proteins. In addition,
the probe sera were pre-adsorbed using antigens from in vitro C. jejuni
cultures. These two measures guarantee that the screened proteins are
expressed in vivo.
Bile acids, includingDOC, can regulate the virulence gene expression
of several gastrointestinal pathogens [17,33,34]. Using microarray
analysis and real-time reverse transcription PCR, Malik-Kale et al. dem-
onstrated that DOC induces the expression of virulence genes. They
concluded that these culture conditions mimic the conditions of in
vivo infection within hosts [17]. In this study, proteins were prepared
by culturing C. jejuni on CCDA medium plus 0.1% DOC, and the expres-
sion proﬁles of the probed in vivo-induced antigens were assessed by
real-time PCR to compare the transcription levels of genes between
bacteria grown on DOC plates and those grown on CCDA plates.
A total of 14 proteinswere identiﬁed by the novel immunoproteomics
method and MALDI–TOF MS in this study. CadF, a 37 kDa outer
membrane protein, mediates the binding between ﬁbronectin in
the extracellular matrix and C. jejuni [35]. CadF was analyzed using
mass spectrometry, and the results showed that the immunogenic
epitope of CadF is cleaved into smaller Fn-binding polypeptides to
avoid the humoral response elicited by the whole protein [36]. In
this study, CadF (37 kDa) and CadF (32 kDa) were both identiﬁed.
The CadF (32 kDa) variant may be the result of post-translational
processing to reduce this protein's immunogenicity under DOC con-
ditions. This result is consistent with the conclusion of Scott et al.
[36]. DnaK and HslU, which belong to the heat shock protein family,
were identiﬁed by this method. DnaK was upregulated under the
DOC culture conditions according to the real-time PCR assay. PorA
is a major outer membrane protein, and its immunogenicity was
conﬁrmed in another study. This protein provides appreciable pro-
tection against colonization by different serotypes of C. jejuni [37].
Using the IVIAT method, 48 proteins, including TufB, that were
expressed in vivo during the infection of humans and chickens
by C. jejuni NCTC 11168 were identiﬁed (unpublished data). TufB,
an outer membrane translation elongation factor, was probed in
this study and validated our experimental conditions for identifying
in vivo-induced antigens.
During the last decade, immunoproteomics has become an interest-
ing method used for identifying immunoreactive proteins, however
there is not report about in vivo expressed antigen. This technique
involves the separation of proteins by 2-DE and Western blotting.
Zhang et al. [19] developed a novel pre-absorbed immunoproteomics
method for the detection of S. suis surface proteins. This new method
may prove to be a useful tool for identifying surface proteins. Hass et
al. [20] developed the immunoproteomics of H. pylori infection and
relation to gastric disease, this approach will greatly assist the search
for more immunogenic proteins for diagnostic assays and vaccine
design. Chung et al. [38] developed the immunoproteomic analyses of
outer membrane antigens of Actinobacillus pleuropneumoniae grown
under iron-restricted conditions.
In conclusion, a novel immunoproteomics-based method was
developed for detection of C. jejuni in vivo-induced antigens,
these proteins may serve as potential vaccine candidates to control
campylobacteriosis. Unlike IVIAT, this method did not use vectors in
E. coli to express proteins in vitro, and therefore, our method allows
the use of native C. jejuni proteins in antigen screening. However, this
method requires the use of sera with very high titers, and the majority
of proteins on the PVDF membranes from 2-DE gels have low abun-
dances. This immunoproteomics-based method may be used for other
hosts or other gastrointestinal pathogens.Acknowledgements
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